Clinical Trial Update: Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating RAD001 (everolimus) with hydroxychloroquine in previously treated metastatic clear cell renal cell carcinoma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)
• RAD001 (everolimus)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Metastatic Clear Cell Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED